Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jim Scopa
AddedMar 31, 2024
UpdatedMay 31, 2026
Jim Scopa

Jim Scopa

Board Member, OneVentures

CrunchbaseLinkedIn

Jim Scopa's Career

OneVentures
OneVentures

Sydney, New South Wales, AU

Board Member· Board
Blade Therapeutics
Blade Therapeutics

South San Francisco, CA, US

Board Member· Board
Neuron23
Neuron23

South San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jim Scopa's Career

OneVentures
OneVentures
Investment FirmInvestment Firm352006Sydney, New South Wales, AU
Board Member· Board

Leadership at OneVentures

Walter LewinWalter LewinBoard Member
Peter GammellPeter GammellBoard Member
Michelle DeakerMichelle DeakerBoard Member
Connie McKeageConnie McKeageBoard Member
Roger Massy-GreeneRoger Massy-GreeneBoard Member
Blade Therapeutics
Blade Therapeutics
Series D$51.5M282013South San Francisco, CA, US
Board Member· Board

Leadership at Blade Therapeutics

Wendye RobbinsWendye RobbinsCEO
Mark TimneyMark TimneyBoard Member
Rana Al-HallaqRana Al-HallaqBoard Member
Luke EvninLuke EvninBoard Member
Peter Van VlasselaerPeter Van VlasselaerBoard Member
Harry DietzHarry DietzFounder

Similar to Blade Therapeutics

Pliant TherapeuticsPliant TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2015Pliant TherapeuticsSouth San Francisco, CA, US · est. 2015

Pliant Therapeutics: A California-based biopharmaceutical company innovating therapies for fibrotic diseases.

Public · $694.9M124
SphynKx TherapeuticsSphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

Seed · $50k30
Mistral TherapeuticsMistral TherapeuticsSan Diego, CA, USFibrosis Treatmentsest. 2011Mistral TherapeuticsSan Diego, CA, US · est. 2011

Mistral Therapeutics: A San Diego-based biotech firm specializing in innovative fibrosis treatments.

Series B · $36.4M6
BLR BioBLR BioKenosha, WI, USBiologics, Diagnosticsest. 2013BLR BioKenosha, WI, US · est. 2013

Kenosha-based BLR Bio, a private biotech firm, specializes in orphan and specialty fibrotic diseases.

Pre-Seed · $780k5
Neuron23
Neuron23
Series C$213.5M612018South San Francisco, CA, US
Board Member· Board

Leadership at Neuron23

Michael AlmstetterMichael AlmstetterBoard Member
Kathy DongKathy DongBoard Member
Adam KnightAdam KnightFounder
Nancy StaglianoNancy StaglianoBoard Member

Similar to Neuron23

Nido BiosciencesNido BiosciencesBoston, MA, USPrecision Medicinesest. 2018Nido BiosciencesBoston, MA, US · est. 2018

Nido Bio: Developing precision medicines for severe neurological diseases using advanced neuroscience.

Series B · $109M30
NeuronityNeuronityMansfield, MA, USMedical Researchest. 2022NeuronityMansfield, MA, US · est. 2022

Neuronity: A Massachusetts-based medical organization curing neurological disorders since 2022.

Pre-Seed · $780k5
Neurona TherapeuticsNeurona TherapeuticsSouth San Francisco, CA, USCell Therapiesest. 2008Neurona TherapeuticsSouth San Francisco, CA, US · est. 2008

Neurona Therapeutics: Leading provider of cell-based medicines for neurological disorders.

Series A · $200.3M58
Neuro42Neuro42Oakland, CA, USMedical Devicesest. 2020Neuro42Oakland, CA, US · est. 2020

neuro42: Innovating advanced MRI tech for diagnosing and treating neurological conditions.

Series B · $12.8M26

Jim Scopa's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailJaeHong ChoiJaeHong ChoiBoard Member · KakaoMason YeoMason YeoBoard Member · Kakao

People Similar to Jim Scopa

Alex GoldsteinAlex GoldsteinBoard Member · VaporoxAlex MartinAlex MartinBoard Member · RenalGuard SolutionsDerek SmallDerek SmallFounder · Luson BioventuresScott KerseyScott KerseyCo-Founder · NeuronPeter BisgaardPeter BisgaardBoard Member · Outpost Medicine